Preview Newsletter
XARELTO Media Monitoring – Week of 11-13-15
-
Xarelto Lawsuit Update: Increasing Number of Wrongful Death Lawsuits Filed in MDL
Nov 6, 2015 | KEYC-TV
By Marc Goldich
BloodThinnerHelp.com reports today on the specifics of wrongful death lawsuits filed in the Xarelto litigation. Lawsuits filed allege that Xarelto causes severe internal bleeding which can further lead to serious injuries and unfortunately death in too many cases. So many of these lawsuits have been filed that in December 2014 a motion was made to consolidate the lawsuits into a multidistrict litigation. The Xarelto MDL currently has more than 1,200 lawsuits filed in it, many of them wrongful death lawsuits. -
Xarelto Lawsuit Alleges Drug Caused Death
Nov 7, 2015 | KYTX-TV
By Marc Goldich
BloodThinnerHelp.com reports on another lawsuit filed against blood-thinning drug Xarelto. This lawsuit was filed by a widow in Florida who claims that use of the drug Xarelto caused her husband’s internal bleeding episodes and, ultimately, his death as well. -
Xarelto Lawsuit Update: Another Wrongful Death Lawsuit Filed in MDL
Nov 10, 2015 | WLNE-TV
By Marc Goldich
BloodThinnerHelp.com reports today on one of the more recent case filed within the Xarelto multidistrict litigation. This case was filed in the MDL by the son of a Georgia resident who passed away from complications following an internal bleeding incident. -
Xarelto Lawsuit Plaintiffs Watch As Manufacturers Use Studies To Their Advantage
Nov 11, 2015 | WCIV-TV
By Marc Goldich
BloodThinnerHelp.com reports on the use of new studies that Xarelto manufacturers have recently highlighted in order to showcase their blood thinning drug as safe. Currently, over 1,900 lawsuits across the nation filed in federal and state courts say otherwise. Plaintiffs in these cases share strikingly similar allegations that the anticoagulant caused them serious health risks, such as uncontrollable bleeding, blood clots, strokes, and heart attacks. -
Xarelto Lawsuit Numbers Limited By Statute Of Limitations
Nov 11, 2015 | KLTV-TV
By Marc Goldich
BloodThinnerHelp.com reports on information regarding the statute of limitations associated with Xarelto lawsuits, which are preventing some individuals from filing. Across the board, statute of limitations are laws that are specifically set to determine a set time frame in which lawsuits are able to be filed by plaintiffs. Generally, this time frame starts on the date an injury is sustained or when it should have been discovered. Time limits from this point vary somewhat from state to state, however, once a limit has reached its expiration, the plaintiff is unable to ever recoup damages from that specific injury. In many states, the statute of limitations on cases is between 2 and 3 years from the date of injury. -
Xarelto Lawsuit Update: Difference Between Xarelto MDL and A Class Action Lawsuit
Nov 12, 2015 | WRDB-TV
By Marc Goldich
BloodThinnerHelp.com reports today explaining the differences between the current Xarelto litigation, a multidistrict litigation, and a class action lawsuit. Both of these are legal systems designed to handle large amounts of cases but they are very different and should not be confused, although sometimes the terms are incorrectly used interchangeably. -
Xarelto Lawsuit Alleges Wrongful Death against Bayer AG And Johnson & Johnson
Nov 13, 2015 | WGFL-TV
By Marc Goldich
BloodThinnerHelp.com reports on another lawsuit filed against manufacturers Bayer AG and Johnson & Johnson regarding blood-thinning drug Xarelto. The suit was filed in the U.S. District Court for the Southern District of Florida by a widow under case number 9:14-cv-80831. The claims within the suit state that her husband’s use of Xarelto ultimately caused his death. -
Seeger Weiss LLP Reports That Xarelto Multidistrict Litigation Bellwether Trial Dates Set For Early 2017
Nov 13, 2015 | PR Newswire
By Seeger Weiss LLP
Seeger Weiss LLP is reporting that the bellwether trial dates have been set for the Xarelto Multidistrict Litigation (MDL). Presiding District Court Judge Eldon Fallon has issued an order for the first four scheduled bellwether trials to commence. The first two will be held in the Eastern District of Louisiana; the first starting on February 6, 2017, and the second starting on March 13, 2017. The next trial will be held in Mississippi on April 24, 2017. The fourth will be held in Texas on May 30, 2017. -
Xarelto Lawsuit Alleges Blood Thinner Caused Life-Threatening Internal Bleeding
Nov 9, 2015 | Top Class Actions
By Ashley Vanover
A new Xarelto bleeding lawsuit was filed against Bayer Healthcare and Janssen Pharmaceuticals, alleging the companies misrepresented the dangers of their new-generation blood thinner, putting users at risk for life-threatening bleeding events. -
Xarelto Internal Bleeding Lawsuit Filed By Surviving Daughters
Nov 6, 2015 | Top Class Actions
By Melissa LaFreniere
A Xarelto lawsuit has been filed by the daughters of a deceased North Carolina man who allegedly died of internal bleeding due to ingesting the blood thinner medication. -
Xarelto Lawsuits and Bleeding Problems
Nov 10, 2015 | Knutson & Casey
Xarelto (rivaroxaban) is a prescription anticoagulant (blood thinner) used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (heart rhythm disorder). The drug is taken by more than 1.4 million people. Manufactured by Bayer and marketed by Johnson & Johnson pharmaceutical company, Janssen Pharmaceuticals, Xarelto is also approved to help reduce the risk of and to treat blood clotting issues associated with deep vein thrombosis (DVT) and pulmonary embolism (PE). -
Xarelto Lawsuit: Drug Caused Severe Bleed Within One Week
Nov 11, 2015 | Top Class Actions
By Tamara Burns
A Xarelto lawsuit claims that the anticoagulant caused a life-threatening bleeding event within one week of use. -
Xarelto Lawsuit Update: Guide to the Ongoing Xarelto Litigation
Nov 11, 2015 | The Legal Herald
By Marc Goldich
Legal Herald provides you today with a clear and helpful guide to the ongoing Xarelto litigation, explaining the MDL and the allegations against the drug. The Xarelto multidistrict litigation has been proceeding for almost one year now and in that time, many events have happened. Today we are providing you with a helpful, up to date guide to the litigation and MDL process for federally filed Xarelto cases. -
A New Xarelto Lawsuit Alleges Drug Caused Man’s Fatal Bleed
Nov 12, 2015 | The Legal Examiner
By Marc Goldich
BloodThinnerHelp.com reports on another lawsuit filed in Vermont against the manufacturers of blood-thinning drug Xarelto. The suit was filed in Vermont federal court under case number 2:14-cv-00159-CR by the daughter of a man who died due to uncontrollable bleeding. The allegations within the suit say that the uncontrollable bleeding and subsequent death was caused by Xarelto. -
Xarelto Bellwether Lawsuits Moving Forward according to These Timelines
Nov 12, 2015 | LawyersandSettlements.com
By Gordon Gibb
It wasn’t that long ago that the first Xarelto lawsuit was filed in response to a blood thinner that was approved and rushed to market without any meaningful way of stopping a Xarelto bleeding issue were one to occur. This, in stark contrast to the old standby Coumadin (warfarin), which carries a secret weapon in the guise of vitamin K, the infusion of which can rapidly reverse the thinning properties of warfarin and allow blood to clot more easily. -
Lawsuit: Xarelto Caused Gastrointestinal Bleeding
Nov 13, 2015 | Wolf & Pravato
A Tennessee woman who developed gastrointestinal bleeding two weeks after first taking Xarelto filed a Xarelto bleeding lawsuit against Janssen Research and Development.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
-
Xarelto Lawsuit Update: Increasing Number of Wrongful Death Lawsuits Filed in MDL
Nov 6, 2015 | KEYC-TV
By Marc Goldich
BloodThinnerHelp.com reports today on the specifics of wrongful death lawsuits filed in the Xarelto litigation. Lawsuits filed allege that Xarelto causes severe internal bleeding which can further lead to serious injuries and unfortunately death in too many cases. So many of these lawsuits have been filed that in December 2014 a motion was made to consolidate the lawsuits into a multidistrict litigation. The Xarelto MDL currently has more than 1,200 lawsuits filed in it, many of them wrongful death lawsuits. More detailed information about the Xarelto litigation can be found on this page.
Wrongful Death Lawsuit Allegations:
Specifically, the Xarelto lawsuits allege that the drug causes uncontrollable internal bleeding which leads to serious injury or death, that the manufacturers of Xarelto failed to warn doctors and patients about the true dangers of the drug, and that the manufactures were negligent in releasing the drug to market without also releasing a corresponding antidote. Xarelto’s lack of corresponding antidote makes the drug very dangerous to its users because if the patient suffers from an internal bleeding injury, there is no way to stop the bleeding. This can lead to life changing serious injuries and even death.
Wrongful Death Lawsuits Filed By Families of Deceased:
The estate of the deceased and their families have the right to bring forward a Xarelto wrongful death lawsuit if they feel that Xarelto was the proximate cause of their loved ones untimely death. These lawsuits are filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. Wrongful death lawsuits can be brought forward to seek compensation for medical expenses from the deceased’s treatment, funeral and burial expenses, loss of financial support and wages while the deceased was ill, future losses, and loss of companionship.
FDA Releases Warnings Regarding Xarelto:
Xarelto was initially approved by the Food and Drug Administration, FDA, in 2011 to treat atrial fibrillation, deep vein thrombosis, and to be used in patients who have recently undergone hip or knee replacement surgery. Soon after its release, studies began to show links between Xarelto and serious internal bleeding and lawsuits making these allegations began to be filed. The FDA currently has two black box warnings attached to Xarelto. The black box warning is the most strict warning the FDA can assign to a drug short of recalling it. It means that there is a reasonable risk of harm associated with taking the medication.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.keyc.com/story/30458686/xarelto-lawsuit-update-increasing-number-of-wrongful-death-lawsuits-filed-in-mdl
-
Xarelto Lawsuit Alleges Drug Caused Death
Nov 7, 2015 | KYTX-TV
By Marc Goldich
BloodThinnerHelp.com reports on another lawsuit filed against blood-thinning drug Xarelto. This lawsuit was filed by a widow in Florida who claims that use of the drug Xarelto caused her husband’s internal bleeding episodes and, ultimately, his death as well.
The suit was initially filed in the U.S. District Court for the Southern District of Florida. Since Xarelto lawsuit numbers rose, however, and were consolidated into multidistrict litigation, it was moved with the MDL to the U.S. District Court of the Eastern District of Louisiana. The complaint is filed under case number 9:14-cv-80831.
In details found within the complaint, the plaintiff states that her husband was prescribed Xarelto on January 10th of 2012 by his doctor. This was done to treat the man’s atrial fibrillation, a condition which can cause blood clots, stroke, or deep vein thrombosis. The medication was taken as a precautionary measure to prevent these health risks, but just a few months after taking it, the man suffered a subdural hemorrhage.
The man was immediately hospitalized because of this hemorrhage, and he remained there for several days. Physicians exhausted all life saving measures in order to stop his bleeding, but due to complications of the bleed, the man died on June 28th of 2012.
Since his death, the man’s widow has stepped up to file a lawsuit containing several allegations against the manufacturers of Xarelto. These allegations state that the husband’s subdural hemorrhage and death could be largely attributed to his use of the drug. Additionally, allegations note that had the couple been aware of the risks associated with the drug, they would have chosen a safer alternative.
In many allegations, Xarelto is regarded as one of the most dangerous blood thinners on the market. This is due to its lack of antidote. When patients taking Xarelto suffer bleeding episodes, physicians cannot stop the bleed and have to resort to life-saving measures such as blood transfusions. Patients taking traditional blood thinners, however, are able to be given vitamin K if bleeding, which counteracts the effects of the blood thinners and allows the blood to clot.
Across the U.S., lawsuits regarding Xarelto continue to be filed. Attorney Marc Goldich is currently helping anyone who has taken the drug and then suffered health problems to explore their legal rights. These individuals may be entitled to compensation. Marc Goldich, Esq. provides free consultations for those involved.
For additional information concerning Xarelto or the severe bleeding risks associated with the drug, or to ask questions, contact Marc Goldich, Esq. by calling 866-425-8902.
http://www.cbs19.tv/story/30460756/xarelto-lawsuit-alleges-drug-caused-death
-
Xarelto Lawsuit Update: Another Wrongful Death Lawsuit Filed in MDL
Nov 10, 2015 | WLNE-TV
By Marc Goldich
BloodThinnerHelp.com reports today on one of the more recent case filed within the Xarelto multidistrict litigation. This case was filed in the MDL by the son of a Georgia resident who passed away from complications following an internal bleeding incident. For more detailed information about the entire Xarelto litigation process, visit this page.
Lawsuit Filed by Son of Georgia Man:
The lawsuit was filed on March 20, 2015 and is filed under federal case number 2:15-CV-00886 in the United States District Court for the Eastern District of Louisiana where the MDL is consolidated. The plaintiff is the deceased’s son and is a resident of Tennessee. The plaintiff is alleging that his father’s uncontrollable internal bleeding event was caused by his Xarelto usage. The complaint details that the deceased was prescribed Xarelto in November 2012 to treat a heart condition he suffered from called atrial fibrillation. In March 2013, the plaintiff’s father suffered from an internal bleeding incident which caused his untimely death. The complaint alleges that his death would not have occurred if the plaintiff and his father were made aware of the real dangers of the drug, stating that they would have opted for one of the safer alternatives on the market.
Allegations Made By Xarelto Lawsuits:
This particular lawsuit alleges that the manufacturers of Xarelto deliberately concealed the dangers of the drug and the fact that it could case irreversible internal bleeding. The lawsuit also alleges that the manufactures were reckless and negligent in releasing the drug onto the market without a corresponding antidote and without informing doctors how to stabilize patients who are experiencing a negative reaction. These are the general allegations made by all of the lawsuits filed in the Xarelto MDL in Louisiana.
Xarelto MDL Information:
The Xarelto MDL was formed in December 2014 after a motion was made to consolidate the growing number of cases filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. The MDL was formed to coordinate pretrial discovery, save on judicial resources, and speed up the judicial process for all parties involved. The MDL is still in the pretrial stages but the bellwether trials, the first few trials of the litigation process, are currently scheduled to start in early to 2017.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.abc6.com/story/30485414/xarelto-lawsuit-update-another-wrongful-death-lawsuit-filed-in-mdl
-
Xarelto Lawsuit Plaintiffs Watch As Manufacturers Use Studies To Their Advantage
Nov 11, 2015 | WCIV-TV
By Marc Goldich
BloodThinnerHelp.com reports on the use of new studies that Xarelto manufacturers have recently highlighted in order to showcase their blood thinning drug as safe. Currently, over 1,900 lawsuits across the nation filed in federal and state courts say otherwise. Plaintiffs in these cases share strikingly similar allegations that the anticoagulant caused them serious health risks, such as uncontrollable bleeding, blood clots, strokes, and heart attacks.
After launching as a new, revolutionary type of blood thinner just a few years ago, Xarelto quickly became associated with adverse health events commonly involving unstoppable bleeding episodes. The drug is being deemed as dangerous due to the fact that it offers no antidote. This means that if someone taking Xarelto is injured and begins to bleed, doctors cannot reverse the drug’s effects and get that individual’s blood to clot. In these situations, physicians have to resort to life-saving measures to try to keep patients alive.
Despite these issues and the many lawsuits now claiming the drug is dangerous, manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) claim that their product is, in fact, safe. Recently, these companies used a new study in an attempt to support this claim.
A recent press release from Johnson & Johnson detailed the results of a Post-Marketing Safety Surveillance study and a Xarelto for Prevention of Stroke in Patients with atrial fibrillation study, which seemed to indicate that “rates and patterns of major bleeding in routine clinical practice were low (2.90 and 2.1 per 100 person years, respectively), and generally consist with those observed in Phase 3 clinical research.” These studies incorporated research from over 45,000 patients according to the company, and were designed to showcase the safety of Xarelto in what they have termed “real-world settings.”
It has been noted that the PMSS study is an ongoing one, which is to take place over the next 5 years and will evaluate patients across the U.S. who use Xarelto once daily for non-valvular atrial fibrillation.
Other studies, however, show conflicting results which highlight potential dangers associated with Xarelto. In a 2015 study, researchers evaluated the difference of several blood thinners, 2 new version anticoagulants and one traditional. They found that: “Although rates of gastrointestinal bleeding seem to be similar in this commercially insured sample of adults in the United States, we cannot rule out as much as a…twofold higher risk of bleeding with rivaroxaban [Xarelto] compared with warfarin.”
Additionally, a 2013 study found that patients given Xarelto showed an increased risk of gastrointestinal bleeding over those receiving standard care. Another 2014 study noted that the drug may be associated with significant liver injury.
At this time, over 1,600 lawsuits against Xarelto have been consolidated to form multidistrict litigation number 2592. As they await trial, additional suits are expected to be filed. Attorney Marc Goldich is currently working to ensure that anyone who has experienced adverse health effects after using Xarelto is able to explore their legal rights. It is possible that these individuals are entitled to compensation.
For additional information on this subject or to ask questions, please contact Marc Goldich by calling 866-425-8902.
http://www.abcnews4.com/story/30495208/xarelto-lawsuit-plaintiffs-watch-as-manufacturers-use-studies-to-their-advantage
-
Xarelto Lawsuit Numbers Limited By Statute Of Limitations
Nov 11, 2015 | KLTV-TV
By Marc Goldich
BloodThinnerHelp.com reports on information regarding the statute of limitations associated with Xarelto lawsuits, which are preventing some individuals from filing. Across the board, statute of limitations are laws that are specifically set to determine a set time frame in which lawsuits are able to be filed by plaintiffs. Generally, this time frame starts on the date an injury is sustained or when it should have been discovered. Time limits from this point vary somewhat from state to state, however, once a limit has reached its expiration, the plaintiff is unable to ever recoup damages from that specific injury. In many states, the statute of limitations on cases is between 2 and 3 years from the date of injury.
Because this is unable to be altered, individuals can be prevented from filing suits, and generally express grief over this outcome. Recently, many lawsuits still within the statute of limitations timeframe have been filed against blood-thinning drug Xarelto, alleging that the drug is dangerous and causes an increased risk of uncontrollable bleeding episodes. These cases have been consolidated to form multidistrict litigation number 2592. Suits are filed against manufacturers Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson & Johnson.
Allegations overwhelmingly state that Xarelto is especially dangerous because it has no known antidote. This means that if an individual taking Xarelto is injured and begins to bleed, the effects of the medicine cannot be reversed to allow their blood to clot. In these situations, physicians are required to resort to life-saving measures to keep the individual alive. More traditional blood thinners offer an antidote through vitamin K. If someone taking these blood thinners is injured and bleeding, physicians can treat them with vitamin K, counteracting the effects of their medication and allowing their blood to clot.
Current plaintiffs allege that manufacturers of Xarelto failed to adequately warn consumers and physicians about the dangers associated with the drug, calling them ‘reckless and negligent’ because they chose to release Xarelto to the market without a corresponding antidote. As the cases included in the current multidistrict litigation await trial, it is expected that more will continue to be filed.
Marc Goldich, Esq. is working to ensure that anyone who used Xarelto and experienced adverse health effects due to the drug is able to explore their rights. He works to make sure that individuals are able to do this before their statute of limitations stops them, and provides free consultations to help attain this. The individuals involved may be entitled to compensation.
To obtain additional information or ask questions, contact attorney Marc Goldich by calling 866-425-8902.
http://www.kltv.com/story/30493866/xarelto-lawsuit-numbers-limited-by-statute-of-limitations
-
Xarelto Lawsuit Update: Difference Between Xarelto MDL and A Class Action Lawsuit
Nov 12, 2015 | WRDB-TV
By Marc Goldich
BloodThinnerHelp.com reports today explaining the differences between the current Xarelto litigation, a multidistrict litigation, and a class action lawsuit. Both of these are legal systems designed to handle large amounts of cases but they are very different and should not be confused, although sometimes the terms are incorrectly used interchangeably.
MDL vs. Class Action:
An MDL is a litigation management system where cases that make the similar allegations against the same defendants are consolidated. An MDL speeds up the entire litigation process for everybody involved by streamlining the pretrial and discovery processes. An MDL also saves on judicial resources. An MDL is different from a class action because an MDL still allows for cases filed in it to be tried separately and for settlements to be decided on an individual basis. This is especially important for litigation such as the Xarelto litigation because the plaintiff’s injuries vary greatly from case to case. In a class action, the settlements are the same for everybody involved, making it very inappropriate for the Xarelto litigation. For more detailed information about the Xarelto litigation, click here.
The Xarelto MDL:
The Xarelto MDL was established in December of 2014 after a motion was made to consolidate the rising number of cases filed against the manufactures of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. There are currently over 1,200 lawsuits filed in the MDL which is consolidated in the United States District Court for the Eastern District of Louisiana. The MDL is presided over by Judge Eldon Fallon.
Allegations Made By Xarelto Lawsuits:
The Xarelto lawsuits filed all generally make the same allegations, which is why they are able to be consolidated. The lawsuits allege that Xarelto causes serious internal bleeding that leads to severe injuries and even death in some patients, that the manufacturers of Xarelto failed to adequately warn patients and doctors about the real dangers of the drug, and that the manufacturers of Xarelto were negligent by releasing the drug onto the market without a corresponding antidote.
Xarelto can be very dangerous without a corresponding antidote. This means that if a patient is taking Xarelto and suffers from an internal bleed, there is no way to stop the bleeding, often leading to serious complications. If a patient taking the traditional blood thinner Warfarin suffers from an internal bleeding incident, a doctor can administer vitamin K and the patient’s blood will clot again, a very different situation than patients taking Xarelto are in.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.wdrb.com/story/30504832/xarelto-lawsuit-update-difference-between-xarelto-mdl-and-a-class-action-lawsuit
-
Xarelto Lawsuit Alleges Wrongful Death against Bayer AG And Johnson & Johnson
Nov 13, 2015 | WGFL-TV
By Marc Goldich
BloodThinnerHelp.com reports on another lawsuit filed against manufacturers Bayer AG and Johnson & Johnson regarding blood-thinning drug Xarelto. The suit was filed in the U.S. District Court for the Southern District of Florida by a widow under case number 9:14-cv-80831. The claims within the suit state that her husband’s use of Xarelto ultimately caused his death.
Further details explain that the husband suffered a subdural hemorrhage, and, due to the fact that he had Xarelto in his system at the time, physicians were unable to stop his bleeding. A subdural hemorrhage, also called a subdural hematoma, is generally the result of some form of head trauma, and indicates that the patient is experiencing a brain bleed. While this is a very serious injury, normally bleeding injuries will clot. Because the man had been taking Xarelto, however, he continued to bleed without clotting.
As a result of these bleeding complications, the plaintiff’s husband passed away on June 28th of 2012. Her complaint indicates that, had they known about the risks associated with the drug, they would never have chosen that anticoagulant, given that alternatives she now considers to be safer were available to them at the time.
Xarelto is considered especially unsafe in many of the lawsuits surrounding it due to the fact that it has no antidote. If someone taking the drug is injured and begins to bleed, doctors are unable to reverse the effects of the medication and get their blood to clot. Instead, they have to resort to life saving measures such as blood transfusions in these instances. Traditional blood thinners offer what many consider to be a safer alternative. They respond to vitamin K. If someone taking a traditional blood thinner is injured, therefore, physicians can administer vitamin K and this will cause their blood to clot.
Although the outcome of this filing has yet to be determined, the woman and her family are confident in their wrongful death lawsuit, and are joined by many other similar suits from across the nation. The complaints filed, which are now said to number over 1,700 federally, have been consolidated for form multidistrict litigation number 2592. It is anticipated that as they await trial, additional Xarelto bleeding lawsuits will be filed.
Attorney Marc Goldich is working to ensure that anyone who has taken Xarelto and has suffered adverse health effects are able to explore their legal rights. He is currently offering free consultations to these individuals, who may be entitled to compensation.
For questions regarding the pending Xarelto litigation, or to request additional information, contact Marc Goldich, Esq. by calling 866-425-8902.
http://www.mygtn.tv/story/30511721/xarelto-lawsuit-alleges-wrongful-death-against-bayer-ag-and-johnson-johnson
-
Nov 13, 2015 | PR Newswire
By Seeger Weiss LLP
Seeger Weiss LLP is reporting that the bellwether trial dates have been set for the Xarelto Multidistrict Litigation (MDL). Presiding District Court Judge Eldon Fallon has issued an order for the first four scheduled bellwether trials to commence. The first two will be held in the Eastern District of Louisiana; the first starting on February 6, 2017, and the second starting on March 13, 2017. The next trial will be held in Mississippi on April 24, 2017. The fourth will be held in Texas onMay 30, 2017.
Xarelto has been connected to serious health issues such as gastrointestinal bleeding, brain hemorrhaging, blood clots, and stroke. Plaintiffs have alleged, in part, that the defendants responsible for developing and marketing Xarelto, Bayer Healthcare, Janssen Pharmaceuticals, and Johnson & Johnson, failed to warn doctors and patients that patients on Xarelto would require medical monitoring and that they were at an increased risk for certain types of bleeding events. Further, plaintiffs claim the manufacturers failed to notify patients that there was no reversal agent that could quickly stop the anticoagulant effects of Xarelto, thereby increasing the risk of uncontrolled bleeding in some patients.
The upcoming bellwether trials are intended to give plaintiffs and their attorneys in the remaining number of cases a better idea as to how juries will respond to certain evidence and testimonies that will be recurring throughout all similar trials.
Several partners at Seeger Weiss LLP serve as leadership in this multidistrict litigation based in the US District Court for the Eastern District of Louisiana.
Seeger Weiss LLP is one of the nation's leading trial law firms handling complex individual, mass and class action litigation on behalf of consumers, investors, injured persons and whistleblowers. The firm, with offices in New York, Philadelphia and New Jersey, represents plaintiffs throughout litigation and as trial counsel in a variety of practice areas, including financial, securities and investment fraud, pharmaceutical injury, consumer protection, qui tam (whistleblower cases), environmental and asbestos exposures, personal injury and medical malpractice, product defect, antitrust, and commercial disputes. For more information, go towww.seegerweiss.com.
For more information on Xarelto or if you believe you have been injured by using Xarelto, go to www.seegerweiss.com/drug-injury/xarelto-lawsuit.
http://www.prnewswire.com/news-releases/seeger-weiss-llp-reports-that-xarelto-multidistrict-litigation-bellwether-trial-dates-set-for-early-2017-300178348.html
-
Xarelto Lawsuit Alleges Blood Thinner Caused Life-Threatening Internal Bleeding
Nov 9, 2015 | Top Class Actions
By Ashley Vanover
A new Xarelto bleeding lawsuit was filed against Bayer Healthcare and Janssen Pharmaceuticals, alleging the companies misrepresented the dangers of their new-generation blood thinner, putting users at risk for life-threatening bleeding events.
According to the Xarelto lawsuit, Kentucky resident Inge P. used Xarelto beginning in April 2014 to treat atrial fibrillation. She subsequently experienced a serious Xarelto bleeding event in May 2014, requiring emergency treatment and long-term hospitalization.
Inge’s Xarelto lawsuit alleges the drug’s manufacturers failed to adequately warn patients and physicians of Xarelto’s bleeding risks. The suit also faults the manufacturers for the lack of a reversal agent in the case of bleeding events.
Inge is seeking compensatory, economic, and punitive damages for Bayer and Janssen Pharmaceutical’s alleged failure to disclose information related to Xarelto’s increased risk of internal bleeding.
What is Xarelto?
Xarelto is a prescription blood thinner manufactured by Bayer and marketed by Johnson & Johnson. In 2011, the Food and Drug Administration (FDA) approved Xarelto to treat deep vein thrombosis, a condition that commonly occurs after hip or knee replacement surgery.
Xarelto is also commonly prescribed to reduce the risk of stroke in patients with a certain type of heart rhythm disorder known as abnormal atrial fibrillation (A-Fib).
Xarelto Injuries and Side Effects
Many patients and physicians have raised concerns about Xarelto’s safety. The most dangerous side effect for people taking Xarelto is uncontrollable bleeding. While the risk is shared by all blood thinners, it is particularly dangerous in Xarelto patients because Xarelto does not have a reversal agent to stop the bleeding.
If a patient on the drug experiences internal bleeding, doctors must find other ways to combat the problem while the drug is flushed from the patient’s system.
According to reports submitted to the FDA, Xarelto was associated with 151 deaths during its first year on the market.
Xarelto Lawsuits
Xarelto has been subject to increasing scrutiny over the past several years, and its manufacturers are alleged to have unlawfully concealed the truth about its tendency to cause life-threatening hemorrhages and internal bleeding. Consequently, a Xarelto MDL (multidistrict litigation) was formed to help consolidate the growing number of cases against the makers of Xarelto.
Most cases involving pharmaceuticals allege that a drug was sold with design, manufacturing, and/or marketing defects, which typically refers to a company’s failure to warn of a certain side effect.
In the case of Xarelto, patients may be able to take legal action in light of claims that Janssen failed to adequately warn doctors and patients about the risk of uncontrollable internal bleeding events.
The Xarelto Lawsuit is Case No. 3:15-cv-246-JGH in the U.S. District Court for the Western District of Kentucky, Louisville Division.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/218820-xarelto-lawsuit-alleges-blood-thinner-caused-life-threatening-internal-bleeding/
-
Xarelto Internal Bleeding Lawsuit Filed By Surviving Daughters
Nov 6, 2015 | Top Class Actions
By Melissa LaFreniere
A Xarelto lawsuit has been filed by the daughters of a deceased North Carolina man who allegedly died of internal bleeding due to ingesting the blood thinner medication.
Plaintiffs Chrissa L. and Betty D. have accused Johnson & Johnson, Janssen Pharmaceuticals and Bayer Healthcare of fraudulent misrepresentation.
They claim the Xarelto manufacturers deceived the medical community and the public in general with claims that the anticoagulant had been tested and was found to be safe and effective.
According to the Xarelto bleeding lawsuit, the manufacturers participated in an aggressive marketing campaign which resulted in $582 million in global sales in its first year. Through these direct to consumer advertisements, manufacturers overstated the efficiency of Xarelto with respect to preventing stroke and systemic embolism.
The plaintiffs state that Xarelto manufacturers also “failed to adequately disclose to patients that there is no drug, agent, or means to reverse the anticoagulation effects of Xarelto, and that such irreversibility could have permanently disabling, life threatening and fatal consequences.”
The Xarelto lawsuit claims that the manufacturers defrauded both the public and the healthcare community with the intent of persuading them to either recommend, dispense or purchase Xarelto.
Chrissa and Betty are seeking more than $75,000 for the alleged wrongful death of their father. They claim to have suffered loss including, but not limited to support, income, services, consortium and guidance.
Xarelto Bleeding Side Effects
The “new” blood thinner Xarelto was FDA approved in 2011 to treat atrial fibrillation and to be used as a blood clot treatment for patients after knee or hip replacement surgery.
Marketed as “more convenient” when compared to the traditional anticoagulant Warfarin (Coumadin), direct to consumer advertisements encouraged patients to ask their physician about Xarelto. Manufacturers claimed that patients taking Xarelto would no longer have to endure regular blood testing or be subject to dietary restrictions.
Within just a few years, Xarelto has gained in popularity. According to manufacturers, it’s the #1 blood thinner in its class with 11 million prescriptions in the U.S. alone.
However, it didn’t take long before the U.S. Food and Drug Administration began receiving reports of serious Xarelto side effects. To date, the agency has received thousands of adverse event reports concerning Xarelto side effects, hundreds of those reports claim Xarelto caused a hemorrhage related death.
Commonly reported Xarelto complications include:
Gastrointestinal bleeding
Low blood pressure
Abnormal liver function
Rapid heartbeat
Reduced platelet levels
Rectal bleeding
Brain hemorrhaging
Bruising
Nose bleeds
Dizziness
Hemorrhaging in the eyes
Xarelto Lawsuits
Currently, Xarelto manufacturers face several hundred complaints in a multidistrict litigation centralized in Louisiana. Legal experts predict the Xarelto MDL will reach more than one thousand claims before the trial begins.
In general, plaintiffs allege that Johnson & Johnson, Janssen Pharmaceuticals along with Bayer did not adequately warn Xarelto consumers that there is no antidote for excessive bleeding.
Contact an Xarelto attorney to find out if you have legal claim.
The Xarelto Internal Bleeding Lawsuit is In re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:15-cv-01066-EEF-MBN and MDL No. 2592 in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/218013-xarelto-internal-bleeding-lawsuit-filed-by-surviving-daughters/
-
Xarelto Lawsuits and Bleeding Problems
Nov 10, 2015 | Knutson & Casey
Xarelto (rivaroxaban) is a prescription anticoagulant (blood thinner) used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (heart rhythm disorder). The drug is taken by more than 1.4 million people. Manufactured by Bayer and marketed by Johnson & Johnson pharmaceutical company, Janssen Pharmaceuticals, Xarelto is also approved to help reduce the risk of and to treat blood clotting issues associated with deep vein thrombosis (DVT) and pulmonary embolism (PE).
XARELTO (RIVAROXABAN) SIDE EFFECTS
While bleeding is a common complication associated with anticoagulants, it is alleged that Xarelto is more dangerous than traditional blood thinners because no antidote exists to reverse its blood-thinning effects. In comparison, Warfarin can be reversed with a dose of Vitamin K. Patients risk irreversible bleeding problems such as internal and gastrointestinal hemorrhaging, both of which can be fatal. Other side effects include pulmonary embolism and stroke.
Despite these safety concerns, neither the manufacturer nor the FDA has issued a recall of Xarelto.
CONTACT AN XARELTO ATTORNEY
If you or someone you love has taken Xarelto and suffered from any of the issues above, you may have an Xarelto claim. Please contact Knutson+Casey Xarelto lawsuit attorney Randy Knutson by e-mail or phone at (507) 344-8888.
PERCENTAGE OF XARELTO PATIENTS WHO EXPERIENCE BLEEDING
The safety of Xarelto compared to warfarin was determined in the clinical trial, ROCKET AF, which involved over 7,000 people. Researchers found the following rates of internal bleeding:
• Major bleeding: Xarelto (5.6%) – Warfarin (5.4%)
• Gastrointestinal (GI) bleeding: Xarelto (3.1%) – Warfarin (2%)
• Bleeding in a critical organ: Xarelto (1.3%) – Warfarin (1.9%)
• Fatal bleeding: Xarelto (0.4%) – Warfarin (0.8%)
• Bleeding resulting in transfusion: Xarelto (2.6%) – Warfarin (2.1%)XARELTO PATIENTS WITH ACUTE ILLNESSESHAVE HIGHER BLEEDING RISK
A study by Reuters in April 2011 compared Xarelto to Lovenox in patients hospitalized for acute medical conditions, such as difficulty breathing, disease, and heart failure. The study found that patients taking Xarelto had higher rates of bleeding and were more than twice as likely to experience bleeding compared to Lovenox. 4.1% of patients taking Xarelto, compared to 1.7% taking Lovenox.
DO I HAVE AN XARELTO LAWSUIT?
If you or somebody you know has experienced a side effect after taking Xarelto, contact an attorney at Knutson+Casey immediately for a free consultation.
http://knutsoncasey.com/services/xarelto-lawsuits/
-
Xarelto Lawsuit: Drug Caused Severe Bleed Within One Week
Nov 11, 2015 | Top Class Actions
By Tamara Burns
A Xarelto lawsuit claims that the anticoagulant caused a life-threatening bleeding event within one week of use.
Plaintiff Anita G. claims she used Xarelto (rivaroxaban) as prescribed by her physician starting in February 2014 to prevent blood clots. After using the medication for only one week, Anita allegedly had bleeding on a knee wound from February through May 2014.
The Xarelto lawsuit claims that the manufacturer did not fully disclose the severe side effects of the product. This omission of safety information has been alleged to cause severe problems for some individuals taking the blood thinner.
According to plaintiff Anita, the bleeding was so severe that it was considered irreversible and life-threatening. Not only did the plaintiff report physical damage from the drug, she also claims financial loss, mental anguish and loss of enjoyment of life.
Seven counts are brought up against Janssen Pharmaceuticals, Johnson & Johnson, as well as Bayer including five counts of product liability (construction or composition defect, design defect, inadequate warning, breaches of express and implied warranty), and breach of warranty of fitness for ordinary use.
Anita is seeking compensatory damages or her pain, suffering, emotional distress and loss of enjoyment of life as well as economic damages to recover lost earnings, medical expenses and other damages.
Xarelto Overview
Xarelto is an anticoagulant drug used to prevent the formulation of blood clots. It was approved in 2011 and is considered a newer generation blood thinning drug compared to Warfarin (Coumadin).
Doctors and physicians were eager to try this new medication that promised to be easier to administer than Warfarin. With manufacturers alleging that Xarelto required no need for a special diet and or frequent monitoring.
Xarelto is used to reduce stroke risk in individuals with atrial fibrillation, and treat deep vein thrombosis (DVT) and pulmonary embolism (PE).
Xarelto Side Effects
Like Warfarin and other blood thinners, the main side effect or complication of using the drug is an increased risk of bleeding complications. Since the drugs prevent clotting, the body can’t use it’s normal method of clotting the blood to stop bleeding from a wound, either internal or external.
With Warfarin, however, there was a reversal agent that could be used to stop the excess bleeding. Fresh frozen plasma and intravenous vitamin K were used as an antidote to curtail the bleeding. With Xarelto, however, no such antidote exists. The medical team is only able to try and control the symptoms after the patient has been instructed to stop Xarelto and the only way to have the blood return to normal and start clotting again is to wait until the medication has been metabolized out of the body.
Xarelto Bleeding Lawsuits
Many individual lawsuits as well as multidistrict litigation (MDL) lawsuits have been filed against the makers of Xarelto for their allegedly defective drug and lack of adequate safety information describing bleeding risks.
If you have suffered from a Xarelto injury with Xarelto gastrointestinal bleeding, pulmonary bleeding, or any other Xarelto bleeding you may qualify for legal compensation. An Xarelto lawyer can review your case at no charge and can assist you in exploring your legal options.
The Xaretlo Lawsuit is Case No. 2:15-cv-01081-EEF-MBN in the U.S. District Court for the Eastern District of Louisiana.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/217901-xarelto-lawsuit-drug-caused-severe-bleed-within-one-week/
-
Xarelto Lawsuit Update: Guide to the Ongoing Xarelto Litigation
Nov 11, 2015 | The Legal Herald
By Marc Goldich
Guide to the Ongoing Xarelto Litigation
Legal Herald provides you today with a clear and helpful guide to the ongoing Xarelto litigation, explaining the MDL and the allegations against the drug. The Xarelto multidistrict litigation has been proceeding for almost one year now and in that time, many events have happened. Today we are providing you with a helpful, up to date guide to the litigation and MDL process for federally filed Xarelto cases. For more detailed information about the Xarelto lawsuits, visit this page.
Xarelto’s Time on the U.S. Market
Xarelto, the brand name for the generic drug rivaroxaban, was first approved by the Food and Drug Administration (FDA) in 2011 to help prevent blood clots and deep vein thrombosis in patients who have recently undergone hip or knee replacement surgery, to treat patients who suffer from atrial fibrillation, and for the general purpose of reducing blood clots. Xarelto is manufactured by pharmaceutical conglomerates Bayer AG and Johnson&Johnson's pharmaceutical unit, Janssen Pharmaceuticals.
Lawsuits Allege Xarelto Has Dangerous Side Effects
Many of the current Xarelto lawsuits allege that the drug has dangerous side effects, mainly that the drug can cause serious internal bleeding that can become uncontrollable and leave the patient with severe injuries. They allege that the drug is particularly dangerous because there is no reversal antidote to reverse its anticoagulant effects. This is very different than traditional blood thinners, like Warfarin, where in the event of an internal bleed a doctor can administer Vitamin K and the patient’s blood will begin to clot again. If a patient taking Xarelto suffers from an internal bleeding injury, there is no way to stop the bleeding.
Xarelto Lawsuits Filed By VictimsThe first Xarelto lawsuit was filed in January 2014. The lawsuit alleged that Xarelto was the cause of the patient's death because of an uncontrollable internal bleeding incident brought on by the drug. Since then, most of the lawsuits filed allege that Xarelto caused the individual uncontrollable internal bleeding which resulted in death or other serious injury. Due to the large and growing number of lawsuits filed, they were consolidated into a Federal Multidistrict Litigation panel in December 2014. The MDL is based in New Orleans, Louisiana and is presided over by Judge Eldon Fallon. In addition to the Federal MDL, a number of lawsuits filed in Pennsylvania have been consolidated into a mass tort group in Philadelphia. The Xarelto MDL is still in the pretrial stages and the bellwether trials will be taking place in early 2017.
FDA Warnings Against Xarelto
The FDA issued a warning in August 2013 that made the public aware that stopping a Xarelto regimen prematurely leads to a higher risk of blood clots and despite this warning, in 2013 Xarelto manufacturers profited with $1.4 billion of Xarelto sales. Xarelto currently has two black box warnings attached to it by the FDA. The black box warning is the strictest warning the FDA can attach to a drug. It means that there is a reasonable risk of harm associated with taking the drug.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.http://legalherald.com/xarelto-lawsuit-update-guide-to-the-ongoing-xarelto-litigation/
-
A New Xarelto Lawsuit Alleges Drug Caused Man’s Fatal Bleed
Nov 12, 2015 | The Legal Examiner
By Marc Goldich
BloodThinnerHelp.com reports on another lawsuit filed in Vermont against the manufacturers of blood-thinning drug Xarelto. The suit was filed in Vermont federal court under case number 2:14-cv-00159-CR by the daughter of a man who died due to uncontrollable bleeding. The allegations within the suit say that the uncontrollable bleeding and subsequent death was caused by Xarelto.Case Facts and Atrial Fibrillation
The father was prescribed Xarelto, as many people are, due to his atrial fibrillation. This is a heart condition that can cause complications such as blood clots or strokes, so many individuals with this condition are put on blood thinning drugs preventatively. After using the medication for a short amount of time, the man was injured and hospitalized. There, physicians diagnosed him with a parenchymal hemorrhage. Because the man’s system still contained active Xarelto, however, his hemorrhage was unable to clot. Doctors tried to save the man for 6 days before he ultimately passed away due to the bleed.
In the daughter’s complaint, she notes that had she and her father been made aware that the drug had no antidote, they would never have used it. She indicated that she now realized there were safer alternatives available, and that Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) were reckless and negligent by marketing a drug without a corresponding antidote.Xarelto And Alleged Warning Label Shortcomings
If someone taking Xarelto becomes injured and bleeds, physicians are unable to get their blood to clot, and have to resort to life-saving measures such as blood transfusions in an attempt to keep the patient alive. Traditional blood thinners do not have this problem. The effects of these drugs can be counteracted with vitamin K, causing blood to clot. This means that if someone using traditional blood thinners becomes injured and bleeds, they can be saved more easily.
As Xarelto lawsuits have recently increased in number, they were consolidated to form multidistrict litigation number 2592. It is fully expected that as these cases await trial, others will join them. Attorney Marc Goldich is currently working to ensure that anyone who has suffered adverse health effects after taking Xarelto has the opportunity to explore their legal rights. These individuals may be entitled to compensation. Marc Goldich, Esq. is offering free consultations to those involved..
For information or questions regarding this press release or Xarelto litigation, contact Marc Goldich, Esq. by calling (866) 425-8902.
http://philadelphia.legalexaminer.com/xarelto-lawsuits/a-new-xarelto-lawsuit-alleges-drug-caused-mans-fatal-bleed/
-
Xarelto Bellwether Lawsuits Moving Forward according to These Timelines
Nov 12, 2015 | LawyersandSettlements.com
By Gordon Gibb
It wasn’t that long ago that the first Xarelto lawsuit was filed in response to a blood thinner that was approved and rushed to market without any meaningful way of stopping a Xarelto bleeding issue were one to occur. This, in stark contrast to the old standby Coumadin (warfarin), which carries a secret weapon in the guise of vitamin K, the infusion of which can rapidly reverse the thinning properties of warfarin and allow blood to clot more easily.
Fast-forward to today, with Xarelto Bleedout lawsuits hovering around 1,700 and climbing - a threefold increase since July. And now various timelines have been issued that will help guide multidistrict litigation going forward, with forthcoming bellwether cases from those consolidated in the US District Court for the Eastern District of Louisiana.
To that end, we are exactly two months away from case selection for the aforementioned bellwether trials, the process for which is scheduled to begin on January 11 of next year. From the myriad of cases now in the pipeline - and those projected to have come forward by the start of the New Year - 40 cases will be shortlisted. Plaintiffs and defendants will choose 10 cases each, with another 20 cases chosen at random.
While it isn’t known how long case selection will actually take, the prescribed window for case selection closes by the first of August, next year.
Things really get going in 2017 with four bellwether trials scheduled within a tight four-month window beginning in March and ending in late May: specifically, as of today the four actual dates are February 6, March 13, April 24 and May 30. While dates are always subject to change, at this juncture those are the four dates.
By then, it is expected that the number of Xarelto lawsuits will be even higher.
As most are aware, Coumadin (warfarin) has and continues to be the gold standard of blood thinners for some 50 years. Warfarin is effective, but requires intensive monitoring of blood and diet to ward against the onset of bleeding issues. This has, over the years, proven labor intensive for both patient and health care provider. The medical community has been looking for an easier alternative for some time.
That alternative finally came a few years ago in Pradaxa, followed closely by Xarelto. The promise of effective blood thinning without the intensive monitoring required of warfarin was the catalyst for an almost universal embrace of both drugs.What many patients did not realize was that unlike warfarin, which can be reversed in most cases with an infusion of vitamin K, Xarelto was brought to market without a similar reversing agent, or antidote. Thus, Xarelto Bleeding complications and related Xarelto side effects can be serious as doctors have less to work with than the gold standard Coumadin.
The manufacturer of Xarelto continues to work on an antidote. Until that goal is achieved, Xarelto patients face the risk of a Xarelto Bleedout that cannot be as easily reversed as it can with warfarin, risking Xarelto Death in the process.
Plaintiffs having filed a Xarelto lawsuit note that they would not have used Xarelto had they been aware of the lack of an available reversing agent. Plaintiffs also assert that defendants were irresponsible in suggesting Xarelto required less monitoring than warfarin, suggesting instead that increased monitoring is not only necessary, but integral to prevent a Xarelto Bleeding Issue or worse, Xarelto Death.http://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-29-21047.html#.VkZAb7erRD8
-
Lawsuit: Xarelto Caused Gastrointestinal Bleeding
Nov 13, 2015 | Wolf & Pravato
A Tennessee woman who developed gastrointestinal bleeding two weeks after first taking Xarelto filed a Xarelto bleeding lawsuit against Janssen Research and Development.
Plaintiff Judy S. alleges in her lawsuit that taking Xarelto caused the severe gastrointestinal bleeding that led to hospitalization and continuing treatment.
The Xarelto bleeding lawsuit claims that neither the plaintiff nor her doctor knew about the risks of excessive internal bleeding associated with Xarelto, because Janssen failed to adequately warn about those risks.
Furthermore, the lawsuit claims that had Janssen given adequate warning about the risks, the plaintiff’s doctor would not have prescribed Xarelto, nor would the plaintiff have agreed to take Xarelto. According to the Xarelto lawsuit, Janssen did not disclose the serious risks associated with Xarelto.
The Xarelto lawsuit alleges that the plaintiff’s gastrointestinal bleeding and suffering occurred because of Xarelto’s negligent and defective design, and further alleges that Janssen knew of this defective design. Specifically, Janssen allegedly knew that gastrointestinal bleeding was more common in Xarelto patients than patients who took other blood thinners.
Xarelto Bleeding Side Effects
Xarelto (rivaroxaban) is a popular blood thinner. In recent years, Xarelto has been targeted in an increasing number of Xarelto bleeding lawsuits.
More than 1,000 Xarelto lawsuits have been filed against Janssen on behalf of Xarelto users who have experienced dangerous Xarelto side effects. These side effects include gastrointestinal bleeding, hemorrhaging, and other adverse bleeding events.
Xarelto was introduced in 2011 as a replacement for Coumadin (warfarin). Xarelto was meant to help reduce the potential for blood clotting in individuals at risk for conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).
Xarelto, unlike generic warfarin and other similar anticoagulants, does not have an available antidote to reverse or reduce the drug’s sometimes dangerous effects, which can make it much more dangerous in the event of a bleeding emergency.
Though most users of Xarelto do not experience its more severe side effects, those who do can undergo a number of potentially severe or even life-threatening bleeding issues that are made even more dangerous by the lack of an antidote.
Xarelto Bleeding Lawsuits
Many Xarelto users have chosen to respond to Janssen’s alleged negligence by filing Xarelto bleeding lawsuits, hoping to gain some kind of compensation for the pain and suffering, as well as financial loss, caused by Xarelto.
If you or someone you know has experienced Xarelto side effects such as Xarelto bleeding, you may be able to join a class action Xarelto bleeding lawsuit.
The Xarelto Bleeding Lawsuit is Case No. 2:15-cv-02277-PD, in the U.S. District Court for the Eastern District of Pennsylvania.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
https://wolfandpravato.wordpress.com/2015/11/13/lawsuit-xarelto-caused-gastrointestinal-bleeding-2/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blog Posts
Full Text of Articles Below
Add recipients
Suggested